Courtney Tate
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Courtney Tate has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
Louise Seymour
Pathology Queensland, Royal Brisbane and Women's Hospital, Qld, Australia
3 shared publicationsDerek N.J. Hart
2 shared publications- Georgina Jane Clark
Dendritic Cell Research, ANZAC Research Institute, Sydney, NSW, Australia
2 shared publications Lynette Chee
Australasian Leukaemia & Lymphoma Grp, Myeloproliferat Neoplasms Working Party, Melbourne, Vic, Australia
2 shared publications- Peter Mollee
Princess Alexandra Hospital and University of Queensland
2 shared publications Steven W. Lane
Australasian Leukaemia & Lymphoma Grp, Myeloproliferat Neoplasms Working Party, Melbourne, Vic, Australia
2 shared publications
Latest Publications
- Open Access
- 30 August 2019
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 25 (11) , 1620-1633
Management of Patients With Erythropoietic Protoporphyria–Related Progressive Liver Disease
Erythropoietic protoporphyria (EPP) is an inherited metabolic disorder of heme synthesis resulting from overproduction of protoporphyrin IX (PPIX), which can lead to progressive liver disease characterized by recurrent EPP crises and end‐stage liver disease. We used the Australian Transplant Registry to identify 5 patients referred for liver transplantation between 2008 and 2017. A total of 4 patients had EPP secondary to ferrochelatase deficiency, and 1 patient had X‐linked EPP. No patient had follow‐up with a specialist prior to the diagnosis of progressive liver disease. There were 3 patients who underwent orthotopic liver transplantation, whereas 2 died while on the transplant waiting list. Parenteral PPIX‐lowering therapy was used in 4 patients and was effective in 3 patients, although 2 of these had rebound porphyria and worsening liver function following a decrease in the intensity of therapy. Early disease recurrence in the allograft following transplantation occurred in 2 patients requiring red cell exchange (RCE) to successfully attain and maintain low PPIX levels, but RCE was associated with hemosiderosis in 1 patient. Allogeneic stem cell transplantation (AlloSCT) was performed in 2 patients. One failed engraftment twice, whereas the second rejected the first graft but achieved full donor chimerism with a second graft and increased immunosuppression. In conclusion, our observations suggest that progressive liver disease needs parenteral PPIX‐lowering treatment with the intensity adjusted to achieve a target Erc‐PPIX level. Because EPP liver disease is universally recurrent, AlloSCT should be considered in all patients with adequate immunosuppression to facilitate engraftment. RCE appears to be effective for recurrent EPP liver disease but is associated with an increased risk of iron overload.
- 30 August 2019
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 25 (11) , 1620-1633
Open AccessManagement of Patients With Erythropoietic Protoporphyria–Related Progressive Liver Disease
Erythropoietic protoporphyria (EPP) is an inherited metabolic disorder of heme synthesis resulting from overproduction of protoporphyrin IX (PPIX), which can lead to progressive liver disease characterized by recurrent EPP crises and end‐stage liver disease. We used the Australian Transplant Registry to identify 5 patients referred for liver transplantation between 2008 and 2017. A total of 4 patients had EPP secondary to ferrochelatase deficiency, and 1 patient had X‐linked EPP. No patient had follow‐up with a specialist prior to the diagnosis of progressive liver disease. There were 3 patients who underwent orthotopic liver transplantation, whereas 2 died while on the transplant waiting list. Parenteral PPIX‐lowering therapy was used in 4 patients and was effective in 3 patients, although 2 of these had rebound porphyria and worsening liver function following a decrease in the intensity of therapy. Early disease recurrence in the allograft following transplantation occurred in 2 patients requiring red cell exchange (RCE) to successfully attain and maintain low PPIX levels, but RCE was associated with hemosiderosis in 1 patient. Allogeneic stem cell transplantation (AlloSCT) was performed in 2 patients. One failed engraftment twice, whereas the second rejected the first graft but achieved full donor chimerism with a second graft and increased immunosuppression. In conclusion, our observations suggest that progressive liver disease needs parenteral PPIX‐lowering treatment with the intensity adjusted to achieve a target Erc‐PPIX level. Because EPP liver disease is universally recurrent, AlloSCT should be considered in all patients with adequate immunosuppression to facilitate engraftment. RCE appears to be effective for recurrent EPP liver disease but is associated with an increased risk of iron overload.
- Open Access
- 1 July 2019
- Published by Oxford University Press (OUP) in BJR|Open
- Vol. 1 (1)
Combination bone marrow imaging using positron emission tomography (PET)-MRI in plasma cell dyscrasias: correlation with prognostic laboratory values and clinicopathological diagnosis
This prospective observational study of positron emission tomography (PET)-MRI findings in 16 consecutive newly diagnosed patients with a plasma cell dyscrasia describes and compares MRI-detected myeloma lesions with 18F-fludeoxyglucose PET-avid myeloma lesions, and correlates quantitative imaging findings to a range of biochemical and prognostic parameters. Simultaneously acquired whole body PET and MRI images were evaluated qualitatively for the presence of focal or generalised abnormalities of bone marrow (BM) on either modality. Quantitative analysis comprised mean standardised uptake values (SUVmean) and fractional water content of the BM measured from PET and chemical shift MRI images of the second to fourth lumbar vertebrae. Final diagnoses comprised symptomatic myeloma (n = 10), asymptomatic myeloma (n = 4) and monoclonal gammopathy of uncertain significance (n = 2). 8/10 patients with symptomatic myeloma demonstrated BM abnormalities on qualitative assessment of MRI compared to 4/10 on PET. BM SUVmean inversely correlated with serum albumin (r = 0.57, p = 0.017). BM water fraction correlated with trephine cellularity and blood platelet count (r = 0.78, p = 0.00039 and r = 0.61, p = 0.0013 respectively). BM water fraction correlated with SUVmean in patients with low plasma cell burden (r = 0.91, p = 0.0015) but not in patients with high plasma cell burden (r = 0.18, p = 0.61). PET-MRI shows promise in both morphological and functional multiparametric quantitative assessment of myeloma. For the first time, multiparametric imaging in myeloma has been shown to predict BM abnormalities and correlate with known biochemical prognostic markers, moving PET-MRI beyond simple diagnostic applications into potential prognostic and treatment selection applications.
- 1 July 2019
- Published by Oxford University Press (OUP) in BJR|Open
- Vol. 1 (1)
Open AccessCombination bone marrow imaging using positron emission tomography (PET)-MRI in plasma cell dyscrasias: correlation with prognostic laboratory values and clinicopathological diagnosis
This prospective observational study of positron emission tomography (PET)-MRI findings in 16 consecutive newly diagnosed patients with a plasma cell dyscrasia describes and compares MRI-detected myeloma lesions with 18F-fludeoxyglucose PET-avid myeloma lesions, and correlates quantitative imaging findings to a range of biochemical and prognostic parameters. Simultaneously acquired whole body PET and MRI images were evaluated qualitatively for the presence of focal or generalised abnormalities of bone marrow (BM) on either modality. Quantitative analysis comprised mean standardised uptake values (SUVmean) and fractional water content of the BM measured from PET and chemical shift MRI images of the second to fourth lumbar vertebrae. Final diagnoses comprised symptomatic myeloma (n = 10), asymptomatic myeloma (n = 4) and monoclonal gammopathy of uncertain significance (n = 2). 8/10 patients with symptomatic myeloma demonstrated BM abnormalities on qualitative assessment of MRI compared to 4/10 on PET. BM SUVmean inversely correlated with serum albumin (r = 0.57, p = 0.017). BM water fraction correlated with trephine cellularity and blood platelet count (r = 0.78, p = 0.00039 and r = 0.61, p = 0.0013 respectively). BM water fraction correlated with SUVmean in patients with low plasma cell burden (r = 0.91, p = 0.0015) but not in patients with high plasma cell burden (r = 0.18, p = 0.61). PET-MRI shows promise in both morphological and functional multiparametric quantitative assessment of myeloma. For the first time, multiparametric imaging in myeloma has been shown to predict BM abnormalities and correlate with known biochemical prognostic markers, moving PET-MRI beyond simple diagnostic applications into potential prognostic and treatment selection applications.
- 25 June 2019
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 60 (10) , 2563-2567
High serum levels of CD178 (soluble FasL) predict for inferior progression free survival in chronic lymphocytic leukemia treated with fludarabine-based chemotherapy
(2019). High serum levels of CD178 (soluble FasL) predict for inferior progression free survival in chronic lymphocytic leukemia treated with fludarabine-based chemotherapy. Leukemia & Lymphoma. Ahead of Print.
- 25 June 2019
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 60 (10) , 2563-2567
High serum levels of CD178 (soluble FasL) predict for inferior progression free survival in chronic lymphocytic leukemia treated with fludarabine-based chemotherapy
(2019). High serum levels of CD178 (soluble FasL) predict for inferior progression free survival in chronic lymphocytic leukemia treated with fludarabine-based chemotherapy. Leukemia & Lymphoma. Ahead of Print.
- 1 May 2018
- Published by Wiley in European Journal of Haematology
- Vol. 101 (2) , 174-184
Prognostic markers in core‐binding factor AML and improved survival with multiple consolidation cycles of intermediate‐/high‐dose cytarabine
Objectives: Core‐binding factor acute myeloid leukaemia (CBF AML) defined by t(8;21)(q22;q22) or inv(16)(p13q22)/t(16;16)(p13;q22) has a favourable prognosis; however, 30%‐40% of patients still relapse after chemotherapy. We sought to evaluate the risk factors for relapse in a de novo CBF AML cohort.Patients/Materials/Methods: A retrospective review of patients from four Australian tertiary centres from 2001 to 2012, comprising 40 t(8;21) and 30 inv(16) AMLs.Results: Multivariate analysis identified age (P = .032) and white cell count (WCC)>40 (P = .025) as significant predictors for inferior OS and relapse, respectively. Relapse risk was higher in the inv(16) group vs the t(8;21) group (57% vs 18%, HR 4.31, 95% CI: 1.78‐10.42, P = .001). Induction therapy had no bearing on OS or relapse‐free survival (RFS); however, consolidation treatment with >3 cycles of intermediate‐/high‐dose cytarabine improved OS (P = .035) and RFS (P = .063). Five patients demonstrated post‐treatment stable q PCR positivity without relapse.Conclusions: >3 consolidation cycles of intermediate‐/high‐dose cytarabine improves patient outcomes Age and inv(16) CBF AML subtype are predictors of inferior OS and RFS, respectively. Stable low‐level MRD by qPCR does not predict relapse Similar OS in the inv(16) cohort compared to the t(8;21) cohort, despite a higher relapse rate, confirms salvageability of relapsed disease.
- 1 May 2018
- Published by Wiley in European Journal of Haematology
- Vol. 101 (2) , 174-184
Prognostic markers in core‐binding factor AML and improved survival with multiple consolidation cycles of intermediate‐/high‐dose cytarabine
Objectives: Core‐binding factor acute myeloid leukaemia (CBF AML) defined by t(8;21)(q22;q22) or inv(16)(p13q22)/t(16;16)(p13;q22) has a favourable prognosis; however, 30%‐40% of patients still relapse after chemotherapy. We sought to evaluate the risk factors for relapse in a de novo CBF AML cohort.Patients/Materials/Methods: A retrospective review of patients from four Australian tertiary centres from 2001 to 2012, comprising 40 t(8;21) and 30 inv(16) AMLs.Results: Multivariate analysis identified age (P = .032) and white cell count (WCC)>40 (P = .025) as significant predictors for inferior OS and relapse, respectively. Relapse risk was higher in the inv(16) group vs the t(8;21) group (57% vs 18%, HR 4.31, 95% CI: 1.78‐10.42, P = .001). Induction therapy had no bearing on OS or relapse‐free survival (RFS); however, consolidation treatment with >3 cycles of intermediate‐/high‐dose cytarabine improved OS (P = .035) and RFS (P = .063). Five patients demonstrated post‐treatment stable q PCR positivity without relapse.Conclusions: >3 consolidation cycles of intermediate‐/high‐dose cytarabine improves patient outcomes Age and inv(16) CBF AML subtype are predictors of inferior OS and RFS, respectively. Stable low‐level MRD by qPCR does not predict relapse Similar OS in the inv(16) cohort compared to the t(8;21) cohort, despite a higher relapse rate, confirms salvageability of relapsed disease.
- Open Access
- 1 January 2018
- Published by Elsevier in JAAD Case Reports
- Vol. 4 (1) , 30-32
Clinical and molecular categorization of progressive, adult-onset cutaneous mastocytosis
- 1 January 2018
- Published by Elsevier in JAAD Case Reports
- Vol. 4 (1) , 30-32
Open AccessClinical and molecular categorization of progressive, adult-onset cutaneous mastocytosis
- 6 April 2015
- Published by AMPCo in Medical Journal of Australia
- Vol. 202 (6) , 330-331
Intravenous OxyContin‐associated thrombotic microangiopathy treated successfully without plasma exchange
Conservative management avoids the morbidity and costs associated with plasma exchange
- 6 April 2015
- Published by AMPCo in Medical Journal of Australia
- Vol. 202 (6) , 330-331
Intravenous OxyContin‐associated thrombotic microangiopathy treated successfully without plasma exchange
Conservative management avoids the morbidity and costs associated with plasma exchange
- 1 September 2009
- Published by Elsevier in Immunobiology
- Vol. 214 (9-10) , 730-736
The CD300 molecules regulate monocyte and dendritic cell functions
- 1 September 2009
- Published by Elsevier in Immunobiology
- Vol. 214 (9-10) , 730-736
The CD300 molecules regulate monocyte and dendritic cell functions